Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX), two companies forever linked by their historic COVID-19 vaccine ...

This flu shot, mFlusiva, was shown in a clinical trial to be up to 27 percent more effective than a standard flu jab ...

In a first, the U.S. has approved an influenza vaccine that relies on mRNA technology—the same technology that underpinned ...

Look deeper, however, and the motive becomes clear: with the Democratic Progressive Party (DPP) authorities trapped in an escalating backlash over the ongoing toxic cooking oil scandal, they are ...

Pfizer's Q2 beat and raised 2026 revenue outlook signal progress, but declining COVID sales and patent losses challenge its ...

This can be interpreted as an indication of preparations for upcoming product launches from the oncology division. The company is currently advancing the clinical development of 14 studies. The focus ...

Experts say messenger RNA (mRNA) vaccines do not alter DNA, contrary to social media posts that resurfaced the long-debunked ...

Vaccines have been reliably and affordably protecting people from diseases worldwide for centuries. Until the COVID-19 pandemic, however, vaccine development was still a long and idiosyncratic process ...

Moderna’s mFLUSIVA is the first mRNA vaccine approved for seasonal flu. Its route to approval was unusual, with the FDA ...